Logo

EIC brings 24 health and medtech innovators to MEDICA 2026 — what is on show and why it matters

Brussels, October 2nd 2026
Summary
  • ›The European Innovation Council will present 24 EIC-backed companies at MEDICA 2026 in Düsseldorf, with 15 supported via the EIC International Trade Fairs Programme 3.0 and 9 via the EIC Tech to Market Programme.
  • ›The delegation covers diagnostics, devices, digital health, AI, robotics, regenerative medicine and advanced manufacturing with solutions ranging from synthetic clinical data to injectable bone graft substitutes and needle-free drug delivery.
  • ›Participating companies receive exhibition space at the EIC Pavilion, tailored business coaching, curated matchmaking and promotional support, yet they still face clinical, regulatory and reimbursement barriers on the road to commercialization.
  • ›MEDICA remains the largest B2B medical trade fair and offers visibility and partnerships, while the EIC programmes aim to accelerate internationalisation though claimed economic outcomes require careful attribution.

EIC brings 24 health and medtech innovators to MEDICA 2026 — what is on show and why it matters

From 16 to 19 November 2026 the European Innovation Council will host a delegation of 24 EIC-backed companies at MEDICA in Düsseldorf. MEDICA is a major global B2B medical trade fair that runs with COMPAMED and attracts manufacturers, clinicians, hospital buyers, distributors and investors. The EIC pavilion will gather firms selected under two EIC Business Acceleration Services initiatives: 15 companies supported by the EIC International Trade Fairs Programme 3.0 and 9 additional awardees participating through the EIC Tech to Market Programme.

The exhibitors span diagnostics and laboratory tools, medical devices, digital health and remote care, AI and robotics, surgical and drug delivery systems, and regenerative medicine. Highlights on the programme include synthetic clinical data platforms, point-of-care EEG, augmented reality for surgery, chip-scale oxygen sensing and injectable bone-regeneration materials. The EIC frames participation as a way to accelerate international growth, but the path from trade-fair exposure to market uptake depends on evidence, regulation and procurement decisions.

Who is in the EIC delegation

Below is a concise catalogue of the 24 companies, their country and the core technology they will showcase. The list indicates whether they are supported under the EIC International Trade Fairs Programme 3.0 or are joining through the EIC Tech to Market Programme.

CompanyCountryTechnology focus (short)EIC Programme
AindoItalyEuroprivacy-certified AI platform to generate privacy-compliant synthetic clinical dataInternational Trade Fairs Programme 3.0
ALTRATECH LIMITEDIrelandUnified platform for multi-modal biomarker detection, sample-to-answer finger-prick testsInternational Trade Fairs Programme 3.0
ArspectraLuxembourgAugmented reality glasses for live imaging, telepresence and surgical navigationInternational Trade Fairs Programme 3.0
ATRO Medical BVThe NetherlandsArtimis meniscus implant to relieve persistent knee pain while preserving joint tissueInternational Trade Fairs Programme 3.0
BestHealth4UPortugalBio2Skin bio-inspired adhesive to protect skin and secure skin-attached medical devicesInternational Trade Fairs Programme 3.0
BrainCaptureDenmarkBC-1, a CE-marked point-of-care EEG system with secure cloud-based remote analysisInternational Trade Fairs Programme 3.0
Butterfly MedicalIsraelMinimally invasive and fully reversible treatment for benign prostatic hyperplasia (BPH)International Trade Fairs Programme 3.0
FaradaIC SensorsGermanyChip-scale oxygen sensor for compact, wearable and portable medical devicesInternational Trade Fairs Programme 3.0
Genera Research Ltd.CroatiaOSTEOGROW-C, an injectable autologous bone graft substitute for bone regenerationInternational Trade Fairs Programme 3.0
HAWK BiosystemsSpainQF-Pro, a functional PD-1/PD-L1 biomarker assay to identify immunotherapy respondersInternational Trade Fairs Programme 3.0
iLoFPortugalBlood-based photonics and AI tool for disease screening and clinical trial recruitmentInternational Trade Fairs Programme 3.0
Inossia ABSwedeninossia® Cement Softener, bone cement technology to reduce new spinal fracture riskInternational Trade Fairs Programme 3.0
neuroCluesBelgiumPortable, calibration-free eye-tracking platform providing objective neurological biomarkersInternational Trade Fairs Programme 3.0
ORIXHAFranceVent2Cool, a liquid ventilation platform for ultra-rapid cooling after cardiac arrestInternational Trade Fairs Programme 3.0
ScienceForBrainLithuaniaBrainProtect, real-time bedside brain physiology monitoring for critical careInternational Trade Fairs Programme 3.0
CHARMItalyCORAL, high-speed coherent Raman imaging microscope for label-free chemical imagingEIC Tech to Market Programme
DEFUSEFranceWearable bioelectronic sensing system plus digital platform to monitor physiological stress in autistic individualsEIC Tech to Market Programme
Dhalion BiotechSwedenOssiGel, injectable, cell-free biomaterial that triggers endogenous bone formationEIC Tech to Market Programme
FlowBeamsThe NetherlandsNeedle-free drug delivery combining microfluidics and laser technologiesEIC Tech to Market Programme
iGraftPortugalSmart, battery-free vascular graft system for continuous, real-time graft monitoringEIC Tech to Market Programme
NanozoomItalyInjectable, targeted nanotheranostic that self-reports tumour accumulation and triggers local therapyEIC Tech to Market Programme
PULSEThe NetherlandsMagneto-acoustic levitation bioprinting device to produce vascularised 3D cardiac models for drug screeningEIC Tech to Market Programme
SpermotileNorwayAutomated sperm selection system for IVF clinicsEIC Tech to Market Programme
Vasc-on-DemandGermanyPlatform to enable functional vascularisation in advanced 3D tissue and organoid modelsEIC Tech to Market Programme

What support the selected companies receive at MEDICA

Exhibition space at the EIC Pavilion:Each selected company will have a dedicated presence at the EIC Pavilion, located at Hall 15, Booth 15C47. The pavilion is positioned as a central hub for networking, meetings and demonstrations during the four-day fair.
Tailored business coaching:The EIC provides coaching to help companies sharpen their value propositions, pitch messages and international market approaches. Coaching is pitched as strategic preparation rather than a substitute for deeper commercial or regulatory advisory work.
Curated matchmaking:Selected companies receive curated introductions to potential investors, corporates, distributors and procurement buyers. Such matchmaking can accelerate partner discovery but converting meetings into signed agreements depends on follow-up, due diligence, certification and procurement cycles.
Visibility and promotional support:The EIC will provide visibility through the pavilion activities and curated promotion. Trade fairs can raise awareness quickly but they are only one component of a market entry strategy that needs clinical data, reimbursement planning and regulatory approvals where applicable.

Technical concepts worth explaining

Synthetic clinical data:Platforms that generate synthetic clinical datasets use generative AI techniques to create realistic but non-identifiable patient records. These datasets can enable algorithm development and validation when real patient data are locked behind privacy or governance constraints. Care is required to validate that synthetic data preserve clinical signal without introducing artefacts, and regulators and purchasers will seek evidence that models trained on synthetic data generalise to real-world populations.
Point-of-care EEG systems:Portable EEG devices capture brain electrical activity outside specialist labs. To be clinically useful they must combine robust signal acquisition, artifact rejection, validated analytics and appropriate data security. Cloud-based remote analysis can scale interpretation but raises questions about latency, clinical governance and cross-border data flows.
Augmented reality for surgery:AR surgical systems overlay imaging or guidance information onto the surgeon's view. Integration with intraoperative imaging, low-latency tracking and sterilizable hardware are technical challenges. Clinical adoption hinges on demonstrable improvements in workflow, accuracy or outcome rather than novelty alone.
Chip-scale oxygen sensors:Miniaturised oxygen sensing can enable wearables or compact monitors in portable devices. Producing accurate, stable and biocompatible sensors at scale requires validated manufacturing processes and calibration strategies to meet medical-grade performance.
Injectable bone graft substitutes and cell-free biomaterials:Injectable, acellular materials that stimulate host bone formation aim to avoid donor tissue and growth factors. They must demonstrate consistent biological activity across patients and be produced under regulatory manufacturing standards. Large-animal models and GLP safety studies are typical prerequisites to clinical trials.
Functional PD-1/PD-L1 biomarkers:Predictive assays that evaluate immune checkpoint pathways seek to identify patients likely to respond to immunotherapies. These tests must be analytically validated and then clinically validated in cohorts treated with the target therapy. Regulatory classification and reimbursement depend on demonstrated clinical utility.
Photonics and AI for blood-based screening:Optical methods combined with AI can detect subtle molecular or cellular signatures in blood samples. Key hurdles include building sufficiently large and diverse training datasets, prospective validation, and ensuring robustness to pre-analytical variability.
Nanotheranostics and triggered local therapy:Nanotheranostics aim to both report on drug accumulation and release therapy in situ. Translating such agents requires careful toxicology, manufacturing controls for nanoscale materials, and regulatory pathways that account for both diagnostic and therapeutic functions.
Needle-free drug delivery:Technologies that replace needles use microfluidics, jet injection or energy-assisted transdermal delivery to administer biologics or small molecules. Demonstrating consistent dosing, patient comfort and regulatory safety for complex biologics are substantial development tasks.
Bioprinting for vascularised 3D tissue models:Bioprinting approaches for vascularised cardiac models aim to improve preclinical drug screening by reproducing tissue structure and perfusion. These platforms can reduce reliance on animal models but must prove assay reproducibility, throughput and predictive value for human responses.

Getting ready for Düsseldorf and EIC logistics

Selected companies will attend a pre-departure session organised by EIC representatives and industry experts. The session will cover positioning, messaging, the mission agenda and practical matchmaking logistics. A second briefing will be held on-site on the eve of the fair. EISMEA staff joining the pavilion include Nassima Ferahtia, Federica Zanca and Andreas Lymberis.

What MEDICA offers and the limitations to watch for

MEDICA remains the largest global meeting place for medical technologies and healthcare buyers. The scale of the show can generate visibility and short lead times to initiate conversations with distributors, hospital procurement teams and investors. Trade fairs are strong for demonstration and first meetings but not a guarantee of contracts. Clinical evidence, regulatory clearance, reimbursement strategy, manufacturing scale and procurement timelines remain decisive for conversion. Companies should treat the fair as an accelerator for contacts and a testbed for messaging rather than a single stop to commercial success.

EIC programmes in play, and claimed impact

EIC International Trade Fairs Programme 3.0:This programme supports internationalisation of EIC-backed SMEs with exhibition slots, coaching, matchmaking and promotional support. The EIC cites that participation in trade fairs in 2024-2025 generated about €70 million in deals and 501 new jobs. Those figures show positive activity but attribution is complex because deal flow can be the result of extended sales cycles, parallel programmes and private funding.
EIC Tech to Market Programme:The Tech to Market Programme is part of the EIC Business Acceleration Services and focuses on helping researchers and deep-tech teams validate market fit and build ventures. It combines entrepreneurial trainings with venture-building support such as team formation, IP and regulatory advice, and investor readiness. For participating teams, joining an EIC pavilion can provide exposure but the programme typically supplements that with targeted training and follow-up.

Practical information and contacts

The EIC Pavilion is located at Hall 15, Booth 15C47 at MEDICA 2026. The fair runs from 16 to 19 November 2026 in Düsseldorf, Germany. Companies and stakeholders with questions about the EIC International Trade Fairs Programme 3.0 should contact the EIC Community Helpdesk and select “EVENT – EIC ITF Programme – MEDICA 2026” in the category field. The EIC MEDICA catalogue is available for download from the EIC Community resources.

Implications for investors, buyers and policy

For investors and hospital procurement teams, the EIC delegation is a concentrated showcase of European medtech innovation. It offers an opportunity to benchmark technologies across diagnostics, devices and digital solutions. For policymakers, the event illustrates how public innovation programmes channel early public funding into commercial opportunities, but it also highlights the continuing need for pathways that link clinical evidence generation, regulatory approval and health-system adoption. Prospective partners should probe clinical evidence, manufacturing readiness and reimbursement strategy during matchmaking discussions.

Final note

MEDICA 2026 will provide an important platform for these 24 EIC-backed innovators to test international interest, find partners and accelerate commercial steps. The EIC support package can shorten some paths to visibility and partners, but real-world deployment in healthcare will still require rigorous clinical and regulatory validation, manufacturing scale-up and business model alignment with healthcare purchasers.

Read More

EIC Fund injects €331 million into 42 European deep tech companies as equity arm reaches full operation

2023-02-06Read Now

How EIC trade fair support helped Croatian agritech AGRIVI win a six figure deal and a tech partnership after GITEX

2026-06-25Read Now

EIC International Trade Fairs Programme 3.0 builds a European pavilion for scaleups — with caveats

2024-06-03Read Now

EIC Service Catalogue: new and targeted services to accelerate EIC-funded projects

2023-09-29Read Now